Quick Answer
Elicio Therapeutics, Inc. reported Diluted EPS of $2.58 per share (loss) for fiscal year 2025.
Elicio Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.58 | +39.3% |
| 2024 | -$4.25 | +38.9% |
| 2023 | -$6.96 | +92.2% |
| 2022 | -$89.27 | -4525.4% |
| 2021 | -$1.93 | +64.5% |
| 2020 | -$5.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.60 | +56.8% | +9.1% |
| June 30, 2025 | -$0.66 | -3.1% | +24.1% |
| March 31, 2025 | -$0.87 | +24.3% | +37.4% |
| September 30, 2024 | -$1.39 | -9.4% | -117.2% |
| June 30, 2024 | -$0.64 | +75.5% | +44.3% |
| March 31, 2024 | -$1.15 | +95.4% | +9.4% |
| September 30, 2023 | -$1.27 | +94.4% | +51.3% |
| June 30, 2023 | -$2.61 | +88.8% | +89.5% |
- Elicio Therapeutics, Inc. showed an increase of +39.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s diluted eps has grown by 52.5% (from $5.43 per share (loss) to $2.58 per share (loss)).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: